PRF Technologies (PRFX) is trading at $1.61 (+14.17%) following the announcement of expanded positive preclinical results for its lead product candidate, PRF-110, on June 25, 2026.
- The study showed PRF-110, an extended-release formulation for post-operative pain, had comparable analgesic efficacy to an approved benchmark, ZYNRELEF, with a slower absorption rate and enhanced tissue retention.
- This positive company-specific news likely contributed to the sharp premarket jump, alongside broader bullish sentiment in tech following Micron’s strong earnings report.